|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The recombinant protein market was valued at USD 125.8 billion in 2020, and it is expected to register a CAGR of 11.2% over the forecast period, 2021-2026. The growth of the recombinant protein market is attributed to the increased expenditure on R&D, the growing prevalence of chronic diseases, rising inclination toward biologics and biosimilars, and advanced recombinant products.
There has been a significant focus on the development of recombinant protein-based vaccines and therapies for the treatment COVID-19, which has been established as a serious burden on the global healthcare economy currently. For instance, in October 2020, Novavax Inc. received USD 4 million from Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of a COVID-19 vaccine based on its proprietary recombinant protein nanoparticle technology platform.
According to OECD, Health at a Glance, 2019 report, almost one-third of people aged 15 years and over reported living with two or more chronic conditions, which include cancer, heart attack and stroke, chronic respiratory problems, and diabetes, on average across 27 OECD countries globally. In Germany and Finland, the prevalence of chronic diseases rises to almost one in two.
Investments have been increasing in research and development, leading to the introduction of new protein therapeutics, which has significantly contributed to the growth and development of the market studied. For instance, in January 2020, Airway Therapeutics Inc. received USD 15.5 million in a Series C financing round for the development of the company's AT-100 novel recombinant human protein rhSP-D, an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD).
Recombinant protein production is found to be a time-consuming procedure, which also requires high costs and maintenance. This, coupled with the regulatory and safety concerns associated with recombinant protein production, is likely to hamper the market growth during the forecast period.
Scope of the Report
As per the scope of the report, recombinant proteins are encoded by recombinant DNA, which involves the insertion of DNA encoding that particular protein into bacterial or mammalian cells. The protein is then purified after getting expressed in these cells. Recombinant protein is produced either by molecular cloning or through polymerase chain reaction (PCR). The recombinant protein market is segmented by product (hormone, growth factor, antibody, enzyme, and other products), application (research application, therapeutic use, and biotechnology industry), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Type of Product|
|Other Types of Products|
Key Market Trends
The Antibody Segment is Expected to Grow at the Fastest Rate Over the Forecast Period
The recombinant antibody production procedure involves the cloning of antibody gene libraries into phage vectors and allowing the phages to infect a host cell line. The host cells then produce daughter phages, which express the recombinant antibodies on their surfaces. The genes can be inserted into an expression system, and the antibodies can be produced in large quantities after a process of selection for antibodies with the desired characteristics.
This procedure has been gaining prominence in recent times, and many companies have adopted this innovative method to apply in various applications. In April 2019, Immunoprecise Antibodies Lt. announced the expansion of its service offerings in therapeutic antibody discovery to select rare, fully human antibodies using its trademark DeepDisplay, a combination of transgenic animal immunization and custom phage display antibody selection.
The market players are adopting various growth strategies to excel in the respective fields. For instance, in June 2020, Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, entered a research collaboration with Celgene, a Bristol Myers Squibb company, to create and develop high-performance recombinant antibodies against diverse targets in human cells.
Companies are also involved in the development of recombinant antibodies for COVID-19 infection. In September 2020, GigaGen Inc., in collaboration with Waisman Biomanufacturing and Goodwin Biotechnology Inc., initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug GIGA-2050 for the treatment of COVID 19.
To understand key trends, Download Sample Report
North America Holds the Largest Market Share
North America is expected to lead the recombinant protein market, owing to the increasing expenditure on research, coupled with the presence of healthcare infrastructure and several major market players. In 2018, Grifols received the US FDA approval to relocate existing immunodiagnostic manufacturing operations to a new consolidated manufacturing facility (CMF) in Emeryville, California, for the production of recombinant proteins.
The chronic diseases that are on the rise across the region are creating a huge demand for recombinant protein therapies, as recombinant proteins are among the proven solutions for treating such diseases. According to GLOBOCAN, 1,95,499 new cancer cases were diagnosed, and 90,222 deaths were reported due to cancer in Mexico in 2020.
Furthermore, the presence of key players in the market and their continuous launches and developments in the region indicate that the market is well-established and is expected to remain so over the forecast period. For instance, in June 2020, Sandoz Canada Inc., a division of Novartis AG, received Health Canada approval for its Ziextenzo, a long-acting recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) indicated to decrease the incidence of infection in patients with non-myeloid malignancies.
During this pandemic period, several big pharmaceutical companies have been investing in recombinant DNA technologies and proteins to address the situation. In April 2020, Sanofi and GSK collaborated to develop vaccines based on Sanofi’s recombinant forms of S-protein COVID-19 antigen and GSK’s adjuvant technology. In addition, certain acquisitions are also happening to boost R&D toward the development of recombinant proteins.
To understand geography trends, Download Sample Report
The recombinant protein market consists of several major players, including Eli Lilly and Company, Merck KGaA, and Novo Nordisk AS, among others. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market positions.
For instance, in November 2020, Eli Lilly and Company received Emergency Use Authorization (EUA) for the investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
In July 2020, Richcore LifeSciences, a Bengaluru-based biotechnology company, established its new manufacturing facility in Tumkur, Karnataka, for the production of recombinant proteins.
In August 2020, Bio-Techne launched a SARS-CoV-1/2 spike receptor-binding domain (RBD) LlamaBody recombinant antibody that blocks the virus from binding to the host receptor, angiotensin-converting enzyme 2 (ACE2).
In May 2020, GeneTex launched recombinant antibodies targeting the viral spike and nucleocapsid proteins. The antibodies are validated for western blot, ELISA, ICC/IF, and as antibody pairs for sandwich ELISA.
In January 2020, Absolute Antibody Ltd launched its Vivopure recombinant mouse antibodies for in vivo research in mouse models.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Expenditure on Research and Development
4.2.2 Growing Burden of Chronic Diseases
4.2.3 Rising Inclination toward Biologics and Biosimilars
4.2.4 Technological Advancements in Recombinant Products
4.3 Market Restraints
4.3.1 Expensive and Time-consuming Production Process
4.3.2 Safety Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Product
5.1.2 Growth Factor
5.1.5 Other Types of Products
5.2 By Application
5.2.1 Research Application
5.2.2 Therapeutic Use
5.2.3 Biotechnology Industry
5.3.1 North America
220.127.116.11 United States (By Type of Product and Application)
18.104.22.168 Canada (By Type of Product and Application)
22.214.171.124 Mexico (By Type of Product and Application)
126.96.36.199 Germany (By Type of Product and Application)
188.8.131.52 United Kingdom (By Type of Product and Application)
184.108.40.206 France (By Type of Product and Application)
220.127.116.11 Italy (By Type of Product and Application)
18.104.22.168 Spain (By Type of Product and Application)
22.214.171.124 Rest of Europe (By Type of Product and Application)
126.96.36.199 China (By Type of Product and Application)
188.8.131.52 Japan (By Type of Product and Application)
184.108.40.206 India (By Type of Product and Application)
220.127.116.11 Australia (By Type of Product and Application)
18.104.22.168 South Korea (By Type of Product and Application)
22.214.171.124 Rest of Asia-Pacific (By Type of Product and Application)
5.3.4 Middle-East and Africa
126.96.36.199 GCC (By Type of Product and Application)
188.8.131.52 South Africa (By Type of Product and Application)
184.108.40.206 Rest of Middle-East and Africa (By Type of Product and Application)
5.3.5 South America
220.127.116.11 Brazil (By Type of Product and Application)
18.104.22.168 Argentina (By Type of Product and Application)
22.214.171.124 Rest of South America (By Type of Product and Application)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abcam PLC
6.1.2 Amgen Inc.
6.1.3 Bio-Rad Laboratories Inc.
6.1.4 Eli Lilly and Company
6.1.5 Merck KGaA
6.1.6 Novo Nordisk AS
6.1.7 Sanofi SA
6.1.8 Thermo Fisher Scientific Inc.
6.1.9 Novartis AG
6.1.10 GeneTex Inc.
6.1.11 Novavax Inc.
6.1.12 GigaGen Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Recombinant Protein Market market is studied from 2018 - 2026.
What is the growth rate of Global Recombinant Protein Market?
The Global Recombinant Protein Market is growing at a CAGR of 11.2% over the next 5 years.
Which region has highest growth rate in Global Recombinant Protein Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Recombinant Protein Market?
North America holds highest share in 2020.
Who are the key players in Global Recombinant Protein Market?
Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Eli Lilly and Company, Novo Nordisk AS are the major companies operating in Global Recombinant Protein Market.